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Abstract
Gout is the most common inflammatory arthritis in adults in the Western world. Characterized by hyperuricemia
and the effects of acute and chronic inflammation in joints and bursa, gout leads to an agonizing, chronically
painful arthritis. Arthritis can also be accompanied by urate nephropathy and subcutaneous urate deposits (tophi).
Exciting new developments in the last decade have brought back the focus on this interesting, crystal-induced
chronic inflammatory condition. New insights include the role of NALP3 inflammasome-induced inflammation in
acute gout, the characterization of diagnostic signs on ultrasound and dual-energy computed tomography imaging
modalities, the recognition of target serum urate less than 6 mg/day as the goal for urate-lowering therapies,
and evidence-based treatment guidelines. A better understanding of disease mechanisms has enabled drug
discovery – three new urate-lowering drugs have been approved in the last decade, with several more in the
pipeline. We now recognize the important role that environment and genetics play in the causation of gout. A
focus on the cardiac, renal, and metabolic comorbidities of gout will help translational research and discovery
over the next decade.
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Editorial
Gout is the most common inflammatory arthritis in the
USA and other Western countries [1–3]. Despite being
four times more prevalent than its autoimmune counter-
part, rheumatoid arthritis (RA), it lags far behind in the
number of publications on the topic (15,475 vs. 129,452
in PubMed search using terms “rheumatoid arthritis” vs.
“gout or gouty arthritis” on 10/9/2016, i.e., by approxi-
mately one-tenth), partially reflecting the interest it trad-
itionally generated from the researchers, pharmaceutical
companies and the federal funding agencies.
Gout is one of the oldest diseases described in humans
and is often considered an “old disease” [4]. So, why has
gout not proven as “popular” as RA among researchers
and clinicians in the past? Is it because gout is not as en-
igmatic as an autoimmune arthritis such as RA? Is it due
to the fact that we have had definitive effective inexpensive
treatment options (allopurinol, probenecid etc.) available
for gout (albeit not effectively used) since the 1960s and
70s? Is it because gout symptoms are intermittent, at least
in the initial phase of the disease? Is it due to the recogni-
tion that behaviors such as overconsumption of certain
foods (including red meat and alcohol) and associated
obesity are risk factors for gout? I remain unsure about
the reasons behind gout’s lack of appeal, but the past
seems to be the past; things are changing very rapidly in
the world of gout. For example, the number of gout publi-
cations have increased 2.5-fold from 290 in 2005 to 753 in
2015 in PubMed (search 10/9/2016). Many exciting devel-
opments in gout, including new drug discoveries, have oc-
curred in recent years and the field continues to evolve at
a dramatic pace. Novel disease mechanisms have been un-
covered and new knowledge with the potential to change
our understanding of inflammation and how it can affect
different body systems has emerged. The sections below
provide a snapshot of some of the key developments.
Gout as an inflammatory disease
The link between inflammasome and associated inflam-
mation in gout is now well understood [5–7]. The NALP3
(also called cryopyrin) inflammasome complex is a key
regulator of the innate inflammatory phenotype of several
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diseases, including gout and type 2 diabetes [5]. Martinon
et al. [6] showed that (1) monosodium urate crystals en-
gaged caspase-1, leading to NALP3 activation and to an
increase in active interleukin (IL)-1b and IL-18 produc-
tion; (2) induced macrophages from mice deficient in vari-
ous inflammasome components, such as caspase-1, ASC,
and NALP3, were defective in urate crystal-induced ac-
tivation of IL-1b; and (3) an impaired neutrophil influx
was also found in an in vivo model of crystal-induced
peritonitis in inflammasome-deficient mice or mice de-
ficient in the IL-1b receptor. Additional evidence of the
role of IL-1 in acute inflammation in gout was shown
in a murine model of gout, where inflammation follow-
ing monosodium urate injection into the mouse ankle
joint was significantly reduced both in mice deficient
for the IL-1 receptor and in wild type mice treated with
the IL-1 inhibitor IL-1 Trap (rilonacept) [8, 9]. Clinical
studies showed that treatment with medications target-
ing anti-IL-1 (IL-1RA [anakinra], IL-1Trap, and anti-
IL-1β monoclonal antibody [canakinumab]) were each
associated with a rapid response in patients with acute
gouty arthritis, thereby reinforcing the argument for an
important role for IL-1β in gout pathogenesis [10–12].
New classification criteria and imaging in gout
In a collaborative effort, the American College of
Rheumatology (ACR) and the European League against
Rheumatism (EULAR) developed the new 2015 classifi-
cation criteria for gout [13]. It is a scoring system based
on a combination of clinical features, signs, and symp-
toms, in combination with radiographic, and ultrasound,
computed tomography (CT), or biochemical findings
(each criteria scored from -4 to 4). The presence of urate
crystals on polarized microscopy, or in its absence, a
total score of ≥ 8, classifies an individual as having gout
[13]. The sensitivity and specificity of these new criteria
were at 92 % and 89 %, respectively. These classification
criteria should help with clinical trials and prospective
cohort studies in gout. Nevertheless, their utility in data-
base and retrospective studies remains to be seen, given
the specificity of the clinical signs and symptoms, and
paucity of such data in clinical records and databases.
The role of imaging in gout has expanded tremen-
dously in recent years, especially with the introduction
and increasing use of ultrasound and dual-energy CT
(DECT) in clinical practice. While many ultrasound
features of gout have been described, two findings that
are considered pathognomonic include the presence of
double contour sign or the starry sky appearance,
caused by urate crystal deposits on cartilage surfaces
(cartilage enhancement presenting as a parallel line to
bony articular surface) versus within the joint fluid, re-
spectively [14, 15]. DECT is a non-invasive, sensitive,
and reproducible method of identifying urate deposits
in joints and in periarticular tissue by allowing a simultan-
eous direct visualization of urate deposits and bone struc-
tures using different display colors [16]. The attenuation
of urate differs significantly from that of bone, depending
on the kilovolt setting of the X-ray tube. However, other
crystalline diseases, such as calcium pyrophosphate depos-
ition, can lead to an ultrasound appearance of double con-
tour similar to that of gout [17]; therefore, it is now
arguable whether double contour is specific for gout or for
crystalline arthritis [18]. These modalities are providing in-
sights into a better understanding of disease pathology
and pathophysiology.
Treatment guidelines, treat-to-target serum urate, and
new drugs for gout
Treatment guidelines for gout have been recently pub-
lished by both the ACR in 2012 [19, 20] and the EULAR
in 2016 [21]. Several key aspects of appropriate manage-
ment are addressed in these treatment guidelines, which
should be helpful to providers since gout care is critically
suboptimal [22]. A controversial recommendation to
limit the maximum dose of allopurinol in patients with
gout and chronic kidney disease by adjusting to creatin-
ine clearance in EULAR guidelines [21] has been chal-
lenged [23] since the risk of hypersensitivity reactions
associated with allopurinol seems to be related to the
starting dose, not the maximal dose [24]. Therefore,
there is currently no rationale to limit the maximum
dose of allopurinol in patients with gout and chronic
kidney disease.
Treat-to-target (T2T) serum urate (sUA) is not a new
concept in gout, but one that has been brought to center
stage by the leading treatment recommendations in the
ACR [19] and the EULAR guidelines [21], as well as by a
recent consensus statement about T2T [25]. The rheuma-
tology community considers the existing evidence regard-
ing T2T to a goal of sUA less than 6 mg/dL in gout as
sufficient based on three key correlates for achieving sUA
less than 6 mg/dL, namely (1) associated benefits of reduc-
tion of gout flares, tophi, and medical care costs by achiev-
ing and maintaining this target [26–28]; (2) the fact that
this sUA target is below the solubility threshold of urate,
which prevents its crystallization in body fluids at 6.8 mg/
dL; and (3) the use of this sUA threshold as a primary out-
come in gout randomized controlled trials (RCTs) for the
drug approval of urate-lowering therapies (ULTs) by the
regulatory authorities [26, 29, 30]. Since there is no way to
achieve the sUA target without monitoring or reassessing
sUA, rheumatologists monitor sUA and aim for an sUA
target level of less than 6 mg/dL. Therapeutic doses of
allopurinol (100–800 mg/day) or febuxostat (40–80 mg/
day) or a combination with uricosurics is often needed to
achieve target sUA. Allopurinol maximum dose need not
be reduced, even in the presence of renal failure, since
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adverse events are related to initial, and not final, allopur-
inol dose [24]; pegloticase is another option. Appropriately
titrated ULT doses can help achieve a near cure for gout
by resolving all urate crystals.
On the other hand, the Agency for Healthcare Research
and Quality determined that the evidence that sUA moni-
toring in patients with gout improves outcomes was insuf-
ficient, and that the lowering of sUA below a threshold had
low level of evidence due to the absence of a randomized
trial testing this strategy [31]. However, evidence to the
contrary has been available as of 2005 and 2011 [30]. In
two replicate pivotal studies of pegloticase, a uricase that
lowers sUA, both the pegloticase biweekly (currently ap-
proved by the US FDA and used in clinical practice) and
monthly dose groups had a higher rate of responders (de-
fined as patient with plasma UA less than 6.0 mg/dL for
80 % of the time or longer during both months 3 and 6), at
38–47 % and 20–49 %, respectively, versus 0 % in the pla-
cebo group [30]. Further, complete resolution of one or
more tophi at the final visit was clinically meaningfully and
statistically significantly higher in both pegloticase dose
groups (biweekly and monthly dosing 40 % and 21 %, re-
spectively, vs. 7 % in placebo) [30]. In the 12-month pivotal
febuxostat active comparator RCT, the respective median
percent reduction in the tophus area by week 52 for sub-
jects receiving febuxostat 80 mg or 120 mg were 83 % and
66 %, respectively, versus 50 % in the allopurinol 300 mg
daily group, in synchrony with the proportion of patients
who achieved target sUA less than 6 mg/dL at the last 3
monthly visits (53 % and 62 % vs. 21 %, respectively) [29].
Thus, achieving target sUA < 6 mg/dl with effective ULT in
randomized trials was associated with better gout out-
comes , i.e., reduction in tophi size and tophi resolution.
Two new ULTs, febuxostat and pegloticase, were ap-
proved in the last decade in several countries, including
the USA and the European Union. Importantly, data on
two new drugs have recently been published. The pipe-
line for gout treatments looks very promising [32]. One
of them, lesinurad, is now approved for use in the USA
and the European Union [33, 34]. Lesinurad is a selective
inhibitor of urate/anion exchanger 1 (URAT1) and organic
acid transporter 4 (OAT4), two urate transporters respon-
sible for the reabsorption of urate from the proximal renal
tubule [35], making it one of the newest approved ULTs.
One of two replicate studies, Combining Lesinurad With
Allopurinol in Inadequate Responders-1 (CLEAR-1 in the
US [36], with CLEAR-2 completed in Europe but not yet
published), showed that 54.2 % of patients in the lesinurad
200 mg plus allopurinol group and 59.2 % in the lesinurad
400 mg plus allopurinol group, versus 27.9 % in the
placebo plus allopurinol arms achieved the primary trial
end-point of sUA less than 6 mg/dL at 6-months, with the
differences being statistically significantly different from
placebo. Renal function elevations were noted in the
200 mg group, but with a greater frequency in the 400 mg
group, and the US FDA approved the 200 mg lesinurad
dose in combination with allopurinol for patients refrac-
tory to allopurinol. The second drug is arhalofenate, which
has a dual action and inhibits urate transporter URAT-1
and proinflammatory cytokines, including IL-1b. This
drug is not yet approved for use. In a RCT, 239 gout pa-
tients were randomized, respectively assigned at a 2:2:2:2:1
ratio to receive 600 mg arhalofenate, 800 mg arhalofenate,
300 mg allopurinol, 300 mg allopurinol plus 0.6 mg col-
chicine, or placebo once a day [37]. Gout flares were sig-
nificantly reduced with 800 mg arhalofenate versus
300 mg allopurinol, with a 46 % decrease in the 800 mg
arhalofenate group (0.66 vs. 1.24 (P = 0.006) and vs. pla-
cebo (P = 0.049)) [37]. Several other treatments with great
potential as ULTs or for acute flares are currently under
development [32].
The comorbidities of gout and hyperuricemia
The association of gout with comorbidities has long
been known [38–40]. In the US National Health and
Nutrition Survey 2007–8 [40], 74 % and 71 % of patients
with gout reported a physician diagnosis of hypertension
and chronic kidney disease stage 2 or higher. Diabetes
and nephrolithiasis are common comorbidities in pa-
tients with gout, with a prevalence of approximately
25 %, and heart failure, myocardial infarction, and stroke
are also commonly observed. New data now emerging
indicate the potential benefit of lowering sUA on non-
arthritic comorbidity load in gout. Many have speculated
on the cardiovascular benefits of sUA lowering [40, 41],
but interest in its reno-protective effect is also emerging
[42]. An ongoing $24.3 million NIH-funded study will
compare allopurinol to placebo in delaying or preventing
early nephropathy in type 1 diabetics without gout [43].
Other studies assessing benefits of sUA lowering in pa-
tients with hyperuricemia and chronic kidney disease
stage 3 are also underway [44].
Future directions
The future of gout is bright. The pipeline for discovery
looks very promising for new therapies for acute gout
and urate lowering. Personalized medicine for gout may
be just around the corner, as our understanding of the
role of genetics and environment improves. While our
knowledge of disease mechanisms in gout has improved
dramatically, the quality of care remains suboptimal and
under-treatment is common. I see an excellent future
for the disease if efforts within the next decade are fo-
cused on a three-pronged approach encompassing (1)
the appropriate use of existing effective therapies with
allopurinol as the key example, as well as others; (2)
novel discovery and approval of new medications for
acute gout and long-term urate-lowering; and (3) a better
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understanding of the role hyperuricemia and chronic
inflammation play in the occurrence of cardiac, renal,
and metabolic comorbidities of gout in order to effect-
ively improve the capacity to prevent and treat these
comorbidities.
Conclusion
In summary, several new developments in gout, including
the recognition of the role that innate immunity plays in
crystal-induced inflammation in gout via activation of
NALP3 inflammasome, the implementation of T2T sUA
less than 6 mg/dL as an important goal relevant to pa-
tients, and new imaging techniques, classification criteria,
and treatment guidelines, all provide a positive outlook for
the treatment of the disease. The launch of new medica-
tions for treatment and a robust pipeline add to the new
opportunities in optimizing gout treatment. The associ-
ated cardiovascular and renal comorbidities and the po-
tential benefit of ULTs on these outcomes identify another
important aspect of gout and its treatment. Gout, which
has long been a disease of high interest for rheumatolo-
gists and clinical immunologists, should now be noticed
by internists and family and general practitioners. I hope
that the federal and other funding agencies become aware
of the transformation of this old disease into an opportun-
ity to learn about inflammation pathways and their impact
on the associated comorbidities.
In recognition of the exciting developments in this
field, BMC Medicine and BMC Musculoskeletal Disor-
ders are launching an article collection focusing on the
research that provides important developments in gout
management and therapy. Authors interested in submit-
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